{"schema_version":"secwatch.filing_event.v1","accession":"0000014272-24-000020","form_type":"8-K","ticker":"BMY","cik":"0000014272","company_name":"BRISTOL MYERS SQUIBB CO","filed_at":"2024-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.157139+00:00","generated_at":"2026-06-06T09:51:44.622476+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Bristol Myers Q4 rev up 1% to $11.5B; Non-GAAP EPS $1.70; FY rev $45.0B; 2024 EPS guide $7.10-$7.40","bullets":["Fourth quarter revenues $11.5B (+1% YoY); GAAP EPS $0.87, Non-GAAP EPS $1.70.","Full-year revenues $45.0B (-2% YoY); GAAP EPS $3.86, Non-GAAP EPS $7.51.","In-line & new product portfolio revenues: +9% in Q4, +7% in FY to $37.9B.","2024 guidance: revenue growth low single-digits; Non-GAAP EPS $7.10-$7.40 (excl. pending acquisitions).","Pipeline: FDA approval of Augtyro; Breyanzi sBLAs accepted; completed Mirati purchase, pending Karuna & RayzeBio."],"urls":{"canonical":"https://secwatch.observer/filing/0000014272-24-000020","json":"https://secwatch.observer/filing/0000014272-24-000020.json","markdown":"https://secwatch.observer/filing/0000014272-24-000020.md","text":"https://secwatch.observer/filing/0000014272-24-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/14272/000001427224000020/0000014272-24-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/14272/000001427224000020/bmy-20240202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T09:51:44.622476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"92aba1ad90f64a45c3ff38e0f64e4db4b4a1b5ff","claim":"BRISTOL MYERS SQUIBB CO reported the fourth quarter of 2023 results: revenue $11,477, EPS GAAP EPS of $0.87 and Non-GAAP EPS of $1.70.","evidence_excerpt":"the decade and beyond.\" 1 Fourth Quarter Full Year $ in millions, except per share amounts 2023 2022 Change Change Excl. F/X** 2023 2022 Change Change Excl. F/X** Total Revenues $11,477 $11,406 1 % 1 % $45,006 $46,159 (2) % (2) % EPS — GAAP* 0.87 0.95 (8) % N/A 3.86 2.95 31 % N/A EPS — Non-GAAP* 1.70 1.82 (7) % N/A 7.51 7.70 (2) % N/A Acquired IPRD charge and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/14272/000001427224000020/0000014272-24-000020-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2023"},{"label":"Revenue","value":"$11,477"},{"label":"EPS","value":"GAAP EPS of $0.87 and Non-GAAP EPS of $1.70"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9d6115e54ddb5c54a397b88eacb7ef2e2998fda9","claim":"BRISTOL MYERS SQUIBB CO reported full year of 2023 results: revenue $45,006, EPS GAAP EPS of $3.86 and Non-GAAP EPS of $7.51. Guidance initiated.","evidence_excerpt":"1 Fourth Quarter Full Year $ in millions, except per share amounts 2023 2022 Change Change Excl. F/X** 2023 2022 Change Change Excl. F/X** Total Revenues $11,477 $11,406 1 % 1 % $45,006 $46,159 (2) % (2) % EPS — GAAP* 0.87 0.95 (8) % N/A 3.86 2.95 31 % N/A EPS — Non-GAAP* 1.70 1.82 (7) % N/A 7.51 7.70 (2) % N/A Acquired IPRD charge and Licensing Income Net Impact","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/14272/000001427224000020/0000014272-24-000020-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year of 2023"},{"label":"Revenue","value":"$45,006"},{"label":"EPS","value":"GAAP EPS of $3.86 and Non-GAAP EPS of $7.51"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}